Cargando…
When disease extent is not always a key parameter: Management of refractory ulcerative proctitis
BACKGROUND: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. OBJECTIVES: To summari...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695253/ https://www.ncbi.nlm.nih.gov/pubmed/34988432 http://dx.doi.org/10.1016/j.crphar.2021.100071 |
_version_ | 1784619535833235456 |
---|---|
author | Michalopoulos, Georgios Karmiris, Konstantinos |
author_facet | Michalopoulos, Georgios Karmiris, Konstantinos |
author_sort | Michalopoulos, Georgios |
collection | PubMed |
description | BACKGROUND: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. OBJECTIVES: To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options. RESULTS: /Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery. |
format | Online Article Text |
id | pubmed-8695253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86952532022-01-04 When disease extent is not always a key parameter: Management of refractory ulcerative proctitis Michalopoulos, Georgios Karmiris, Konstantinos Curr Res Pharmacol Drug Discov Medical Management of IBD Edited by Joana Torres and Ryan Ungaro BACKGROUND: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. OBJECTIVES: To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options. RESULTS: /Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery. Elsevier 2021-12-11 /pmc/articles/PMC8695253/ /pubmed/34988432 http://dx.doi.org/10.1016/j.crphar.2021.100071 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Medical Management of IBD Edited by Joana Torres and Ryan Ungaro Michalopoulos, Georgios Karmiris, Konstantinos When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title_full | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title_fullStr | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title_full_unstemmed | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title_short | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
title_sort | when disease extent is not always a key parameter: management of refractory ulcerative proctitis |
topic | Medical Management of IBD Edited by Joana Torres and Ryan Ungaro |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695253/ https://www.ncbi.nlm.nih.gov/pubmed/34988432 http://dx.doi.org/10.1016/j.crphar.2021.100071 |
work_keys_str_mv | AT michalopoulosgeorgios whendiseaseextentisnotalwaysakeyparametermanagementofrefractoryulcerativeproctitis AT karmiriskonstantinos whendiseaseextentisnotalwaysakeyparametermanagementofrefractoryulcerativeproctitis |